The use of weight loss dietary supplements is prevalent in the United States, and over the past decade, there has been tremendous growth of the use of these products. It is well documented that ephedra-based products are associated with various cardiovascular adverse effects. With new restrictions placed on such products, companies are now manufacturing caffeine-based ephedra-free herbal supplements. We present the case of 36-year old, previously healthy female who developed malignant hypertension and aortic dissection while taking various caffeine-based dietary supplements. Given the lack of research studies in regards to their safety and efficacy, judicious care should be taken with the use of dietary supplements, including those designated as ephedra-free.
The prevalence of obesity has increased markedly in the United States. Successful weight loss strategy involves long-term life style changes such as reducing calorie consumption and increasing physical activity . In the United States, dietary supplements for weight loss are not recommended for losing weight due to concerns about efficacy and safety. Despite these rising concerns and several United States Food and drug Administration (FDA) warnings, supplements are an appealing alternative or adjunct for weight management for many people. Dietary supplements are widely available and there is little information available on who is using these products and how they are typically used . It is well documented that ephedra-based supplements are associated with adverse reactions, especially cardiovascular and neurological injuries [3-5]. With new restrictions from FDA on ephedra, companies are now manufacturing caffeine-based ephedra-free dietary supplements and recent reports suggest that they may have potential, serious side effects that are similar to that of ephedra-based products [6,7]. We report the case of a patient who developed malignant hypertension and aortic dissection associated with the excess use of multiple caffeine-based ephedra free weight loss dietary supplements.
A 36-year-old, previously healthy Hispanic female with no significant past medical history and no prior history of hypertension presented to the emergency room with sharp retrosternal chest pain radiating to the back. She was 165 centimeter tall and weighed 70 kilogram. She was a housewife and mother of two living children. She smoked one pack of cigarettes a day for more than ten years. For 3 months prior to presentation, she had been taking 18-20 tablets of caffeine-based weight loss pills daily, which was higher than the recommended daily dose. Each tablet contains 60-100 mg of caffeine and she was taking 1080 mg to 2000 mg of caffeine daily. She denied the use of other medications, stimulants, herbal, alcohol and illicit drugs. She said that she had lost approximately 20-25 kilograms in last 3 months. No family history of hypertension, diabetes or coronary artery disease. She denied palpitation, chest pain, insomnia, headache, abdominal pain or increase in urination.
On presentation, her blood pressure was found to be 220/110 mm Hg in right arm and 230/118 mm Hg in left arm. Her initial work-up included an electrocardiogram which showed T-wave inversion in leads III, aVF and V6. A complete blood count showed hemoglobin 12.9 g/dl (normal: 12.0-16.0 g/dl), white blood cell count 15.1 k/ul (normal: 4.0-11.0 k/ul) and platelet count 231 k/ul (normal: 150-450 k/ul). Serum basic metabolic panel showed sodium 132 mmol/L (normal: 135-145 mmol/L), potassium 3.3 mmol/L (normal: 3.5-5.3 mmol/L), chloride 103 mmol/L (normal: 95/105 mmol/L), bicarbonate 23 mmol/L (normal: 22-31 mmol/L), creatinine 1.3 mg/dl (normal: 0.6-1.3 mg/dl), calcium 8.3 mg/dl (normal: 8.6-10.3 mg/dl), and anion gap 6 mmol/L (normal: 7-17 mmol/L). Liver function test showed normal aspartate transaminase (15 U/L; normal: 0-55 U/L), alanine transaminase (23 U/L; normal: <45 U/L), alkaline phosphatase (55 U/L; normal: 34-104 U/L) and albumin (3.5 g/dl,normal:3.0-5.1 g/dl). Urinalysis showed only elevated specific gravity of 1.031(normal: 1.005-1.03). There were no crystals, protein and glucose in the urinalysis. Troponin I level was less than 0.030 ng/ml (normal: 0.0-0.049 ng/ml). Urine and serum toxicology screens were negative for cocaine, amphetamine, marijuana, benzodiazepines, barbiturates and phencyclidine. A chest X-ray did not show any infiltrate, consolidation, effusion or mediastinal widening. A computed tomography aortogram showed aortic dissection involving the posterior aspect of the arch extending into the common iliac arteries and right proximal external iliac artery. The dissection extended into the left subclavian and axillary arteries. There was narrowing of the origin of the right renal artery due to dissection (Stanford type B dissection) (Figure 1,Figure 2, & Figure 3.)
Aortic dissection involving the thoracic aortic arch at the mid portion in the posterior aspect of the arch (thick arrow). Thoracic aorta was of normal caliber (27.3 mm).
- Blanck HM, Khan LK, Serdula MK: Use of nonprescription weight loss products. JAMA 2001, 286:930-935.
- Blanck HM, Serdula MK, Gillespie C, Galuska DA, Sharpe PA, Conway JM, Khan LK, Ainsworth BE: Use of nonprescription dietary supplements for weight loss is common among Americans. J Am Diet Assoc 2007, 107:441-447.
- Miller SC: Safety concerns regarding ephedrine-type alkaloid-containing dietary supplements. Mil Med 2004, 169:87-93.
- Moawad FJ, Hartzell JD, Biega TJ et al: Transient blindness due to posterior reversible encephalopathy syndrome following ephedra overdose. South Med J 2006, May: v99.
- Bent S, Tiedt TN, Odden MC et al: The relative safety of ephedra compared with other herbal supplements. Ann Intern Med 2003, 138:468-471.
- Nasir JM, Durning SJ, Ferguson M et al: Exercise-induced syncope associated with QT prolongation and ephedra-free Xenadrine. Mayo Clin Proc 2004, 79:979-982.
- Bouchard NC, Howland MA, Greller HA et al: Ischemic stroke associated with use of an ephedra-free dietary supplement containing synephrine. Mayo Clin Proc 2005, 80:541-545.
- Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body; final rule. Federal Register 65. (6 January 2000): 999-1050.
- Ko RJ: Adulterants in Asian patent medicines. N Engl J Med 1998, 339:847.
- Pillans PI: Toxicity of herbal products. NZ Med J 1995, 108:469-471.
- Deng JF, Lin TJ, Kao WF, Chen SS: The difficulty in handling poisonings associated with Chinese traditional medicine: a poison center experience for 1991-1993. Vet Hum Toxicol 1997, 39:106-114.
- Klein CJ: Recommendation for adverse event monitoring programs for dietary supplements. Bethesda, MD: Life Sciences research Office; 2004.
- Jacob P: Hemodynamic effects of ephedra-free weight-loss supplements in humans. Am J Med 2005, 118:998-1003.
- Walker AM: The relation between voluntary notification and material risk in dietary supplement safety. 2000, . Available at: [http://www.fda.gov/orhm/dockets/oon1200]. Accessed August 28, 2008